Biomarker profiling study for advanced head and neck cancer patients
Part of Cancer clinical trials.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have head and neck squamous cell carcinoma that has spread or cannot be removed and is not treatable with local therapies.
- You should be scheduled to receive immunotherapy (a PD-1 or PD-L1 inhibitor) as your first treatment for this stage of cancer.
- You must provide a tumor tissue sample for analysis.
- You cannot have had a recurrence within 6 months of previous chemotherapy or chemoradiotherapy.
- If you have had another cancer in the last 2 years (except certain low-risk types), you may not qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with head and neck cancer that has not spread to distant parts of the body. It is a non-treatment study that will look at the molecular features of your tumor from a biopsy sample to help guide future treatment decisions.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This study is looking for people with advanced head and neck cancer who have already received immunotherapy plus chemotherapy as their first treatment. Researchers will study your tumor tissue and proteins to find better ways to use immunotherapy.
This trial collects tumor samples from people with head and neck squamous cell cancer to study why some cancers stop responding to standard treatments like cetuximab. The goal is to learn how resistance develops so better therapies can be found.
This study looks at “immune signals” in blood, saliva, and stool to learn more about head and neck cancers (especially squamous cell carcinoma). It may help researchers find patterns that improve understanding of disease or how treatment should be guided.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.